Vishal Vashistha

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 12

Top Topics

Epidermal Growth Factor Receptor

Positron Emission Tomography

Radical Prostatectomy

Top Venues

JCO precision oncology

JCO oncology practice

European journal of cancer care

This page only lists publications with an associated author ORCID identifier.

Publications

Vishal Vashistha, Evangelia Katsoulakis, Aixia Guo, Meghan J Price, Sara Ahmed, Michael J Kelley
Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program. JCO precision oncology 7 (2023)
Christina D Williams, Mina A Allo, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael Kelley
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PloS one 18 (2) (2023)
Katherine Ismei Zhou, Vishal Vashistha, Aixia Guo, Sara Ahmed, Michael J Kelley
Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans. JCO precision oncology 7 (2023)
Vishal Vashistha, Evangelia Katsoulakis, Aixia Guo, Meghan J Price, Sara Ahmed, Michael J Kelley
Molecular-Guided Off-Label Targeted Therapy in a Large-Scale Precision Oncology Program. JCO precision oncology 7 (2023)
Christina D Williams, Mina A Allo, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael Kelley
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PloS one 18 (2) (2023)
Christina D Williams, Mina A Allo, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael Kelley
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PloS one 18 (2) (2023)
Christina D Williams, Mina A Allo, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael Kelley
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PloS one 18 (2) (2023)
Christina D Williams, Mina A Allo, Lin Gu, Vishal Vashistha, Ashlyn Press, Michael Kelley
Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. PloS one 18 (2) (2023)
Avneet Garg, Hariharan Iyer, Vinita Jindal, Vishal Vashistha, Gopal Chawla, Pawan Tiwari, Saurabh Mittal, Karan Madan, Vijay Hadda, Randeep Guleria, Hem C Sati, Anant Mohan
Evaluation of delays during diagnosis and management of lung cancer in India: A prospective observational study. European journal of cancer care 31 (5) (2022)
Ruchir Raman, Varun Ramamohan, Anurag Rathore, Deepali Jain, Anant Mohan, Vishal Vashistha
Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. Asia-Pacific journal of clinical oncology (2022)
Meghan J Price, Vishal Vashistha, David Winski, Michael J Kelley, Rhonda L Bitting, Robert B Montgomery
Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors. JCO precision oncology 6 (2022)
Vishal Vashistha, Jenna Armstrong, David Winski, Pradeep J Poonnen, Bradley J Hintze, Meghan Price, Jane L Snowdon, Dilhan Weeraratne, David Brotman, Gretchen P Jackson, Michael J Kelley
Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. JCO oncology practice 17 (7) (2021)